Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cryo-Touch III · 1 trial · 2 indications
* Effectiveness endpoint: Wrinkle severity in the target area in animation at 30 days post-treatment as rated by the investigator using the 5-point grading scale. * Safety endpoint: Incidence of device-related serious adverse events (DSAE).
| Arm | Type | Description |
|---|---|---|
| Treatment | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cryo-Touch III | DEVICE | Percutaneous treatment with the device |
Inclusion Criteria: * Age 30-70 years * Subject has a glabellar and/or forehead wrinkle rating by investigator of at least 2 in animation on the 5-point Wrinkle Scale (5WS)\* * Subject has signed institutional review board (IRB)-approved informed consent form Exclusion Criteria: * Subject takes a...
Cryo-Touch III is an investigational device being studied for the treatment of facial wrinkles and skin aging. It is in Phase 2 clinical development for these dermatological conditions. The device is being evaluated in a clinical trial in the United States.
Cryo-Touch III is being developed by Pacira BioSciences, Inc., a company traded on the NASDAQ under the ticker symbol PCRX. The company is conducting clinical research on this device for facial wrinkles and skin aging.
Cryo-Touch III is in Phase 2 clinical development. It is an investigational device and has not been approved by the FDA. One Phase 2 study has been completed, and the device remains under investigation for facial wrinkles and skin aging.
Cryo-Touch III has one completed clinical trial, identified as NCT01379365, titled "Cryo-Touch III Refinement Study Investigational Plan." This Phase 2 study enrolled 88 participants in the United States and evaluated the device for facial wrinkles and skin aging.
No alternative names for Cryo-Touch III have been reported. The device is identified by this name in its clinical trial documentation. It is being studied specifically for facial wrinkles and skin aging by Pacira BioSciences.